Ulysse Biomed's HPV solutions are confirmed among the global best practices for molecular testing of Human Papilloma Virus.
A recent article analysed the context of HPV molecular tests available on the diagnostic market. New tests and test variants have been released over the past three years. "However, only 21% of all HPV tests currently available on the market [...] had data to support the claim that the clinical and/or analytical performance characteristics of the tests are in line with agreed requirements in the HPV community. [...] In conclusion, only a relatively small pool of HPV tests currently on the market meets the operational/performance characteristics required to address the global challenge of cervical cancer screening,' the article states.
Ulisse Biomed's HPV molecular tests meet all quality, operational and performance requirements, being also included in the latest report of validated tests of the Italian Group for Cervicocarcinoma Screening (GISCi). "At Ulisse Biomed, thanks also to the integration with Hyris and its proprietary solution, we work to provide quality, effective and efficient solutions for laboratory operators and clinicians," says Gabriele Salaris, Head of Marketing and Sales at Ulisse Biomed. "We started with HPV genotyping solutions, continued with Sexually Transmitted Diseases and are now focusing on innovative syndromic panels that will soon be released to the market," he concludes.
